Dr. Agarwal’s Optimistic Outlook Despite FY26 Greenfield Drag

Dr. Agarwal’s Health Care Limited — Q4 FY26 Earnings Call (May 21, 2026)

1. Overall Tone of Management: Optimistic

• Management repeatedly emphasizes milestones and delivery: “for the first time… crossed INR 2,000 crores of revenue” and “we delivered on each one” (growth, profitability, expansion).
• Forward-looking language is confident: “expect growth to sustain at a similar pace” and “EBITDA margins to stay stable”.
• Even when risks appear (approvals, ramp-up), they are framed as manageable delays: “we don’t see too much of a challenge” and “12 to 18 months… to stabilize”.

2. Key Themes from Management Commentary

• Strong FY26 financial delivery with margin expansion
• Revenue from operations: INR 2,080 cr (+21.6% YoY)
• Ind AS EBITDA: INR 614 cr (+22.2% YoY); margin 28.9% (+31 bps)
• PAT: INR 168 cr (+52.4% YoY); PAT margin 7.9% (+164 bps)
• Aggressive organic expansion via greenfields
• Q4: 19 new greenfield facilities commissioned (including 7 surgical centers)
• FY26: 269 facilities total; 30 lakh+ patients, 3.23 lakh surgeries
• “one new facility every week” since FY23; FY26 added across 26 new cities
• Case-mix premiumization / complex surgery growth
• High-end cataract: 26.3% of cataracts (vs 22.5% in FY25)
• Femto/robotic cataract: +87% YoY, 5,900+ procedures
• Lenticular (SMILE): +19% YoY
• Retinal surgeries: +23% YoY
• Operational leverage narrative
• Q4 EBITDA margin 30.2% (highest quarterly margin for the year) despite 19 new facility openings
• Delhi-NCR scaling as a key growth engine
• Delhi entry end-May 2025; multiple launches through FY26
• Expect 7–8 additional centers in Delhi-NCR over next 12–18 months
• Technology platform / scalability
• “Neo” AI-ready hospital management system: built to scale beyond 5,000 branches and 2 million patients daily
• Merger progress (holding + listed subsidiary)
• NCLT Chennai bench allowed first motion; meetings scheduled July 2, 2026
• Management expects completion timeline later in the call (see Guidance/Outlook)

3. Q&A Analysis

Theme A: Capex, acquisition cash outflows, and facility mix

• Core questions
• Capex breakdown for FY27’s 60 facilities (40 surgical, 20 clinics)
• Cash outflow for acquisition-related payments in FY27 and FY26
• Greenfield vs new-region split for FY27 additions
• Management response
• FY27 capex/outflow: INR 380–400 cr (includes CMS facility)
• Acquisition-related payments: INR 60–65 cr in FY27; ~INR 85 cr in FY26
• West tertiary facility: confirmed one tertiary facility in West (Thane Main Hospital)
• FY27 centers: all organic (partners only if “right price”, not in pipeline)
• FY26 net clinic closures: closed five eye clinics in FY26 (for net additions)
• New cities entered: 26 new cities in FY26; for FY27 “exact number” of new markets to be provided later
• Notable / evasive elements
• FY27 greenfield/new-region count not quantified (“I’ll have to come back”).
• Mature vs emerging margin accretion not given precisely (see Theme C).

Theme B: Subsidiary (AEHL) expenses, timeline, and merger-related costs

• Core questions
• Why “other expenses” rose in Q4 (subsidiary financials)
• AEHL Chennai facility completion timeline
• Merger completion timeline and whether delays exist
• Management response
• Q4 other expenses: one-time merger process expenses (~INR 80 lakhs) + corporate office rent (moved Dec) + Facebook marketing (annual ~INR 3.3 cr)
• AEHL Chennai project: target launch by Oct 1, 2026
• Merger timeline:
  • EGM/creditor-shareholder voting: July 2, 2026
  • “another five months or so” after voting; later clarified as 5–6 months and “by end of this year, Q3…”
• Notable / evasive elements
• Quarter-wise breakdown of subsidiary “other expenses” beyond Q4 merger cost was not fully provided (“probably we can connect separately”).
• Merger timeline language is not fully consistent across the call (see Red Flags / Consistency).

Theme C: Margins, unit economics, and “drag” from new facilities

• Core questions
• Margin accretion for mature facilities / operating leverage
• Whether new facility “drag” will recur in FY27 (directionally INR 30–40 cr)
• Operating losses for new greenfield cohorts (FY26 vs FY25)
• Revenue for FY26 cohort where INR 30 cr drag was cited
• Management response
• Mature facility margin accretion: cannot quantify exactly
• Greenfield cohort drag:
  • FY26 new branches: loss ~INR 30 cr (unit economics perspective)
  • FY25 similar cohort drag: ~INR 21 cr
• Delhi cohort: losses ~INR 30 cr from Delhi; per-branch loss expected to reduce from FY27 onward
• Incremental drag directionally: “Yes… directionally, you’re absolutely right” (implying continued drag with higher surgical openings)
• Revenue for the cohort: management said they’ll come back on exact number
• Notable / evasive elements
• Repeated inability to provide exact mature facility margin accretion and exact cohort revenue.
• “Directionally” answers dominate where investors likely want quantification.

Theme D: Refractive softness and long-term refractive outlook

• Core questions
• Drivers of refractive softness vs cataract strength
• Sustainability of mature facility growth (vintage performance)
• Management response
• Refractive softness attributed to industry softness; also cataract growing faster
• High-end refractive (Lenticular/SMILE) growing faster: +19%
• Long-term: refractive remains supported by vision issues; “no long-term issue”
• Insurance support: “talking to insurers… once that gets settled” could help
• Notable / unusually strong
• Confidence on long-term refractive: “we don’t see a long-term issue” (but near-term depends on insurer settlement—conditional).

Theme E: Operational standardization and talent pipeline

• Core questions
• How protocols/talent are homogenized across India
• Paramedical attrition and wage inflation
• Management response
• “clinical board” of senior doctors ensures standardization of outcomes
• Optometrist pipeline: in-house institute of optometry (3-year training + 1-year internship)
• Doctor training: three institutions (Chennai, Tirunelveli, Cuttack) + program in Vashi
• Paramedical attrition: 21%–25%
• Wage increments: ~9.5%–10%
• No major evasiveness.

4. Guidance / Outlook

Explicit guidance (quantitative)

• FY27 facility commissioning plan: 60 new facilities total
• 40 surgical + 20 clinics
• Regional additions: South +24, North +16 (highest ever), West +15
• FY27 capex/outflow: INR 380–400 cr (includes CMS facility)
• Growth outlook: “expect growth to sustain at a similar pace compared to the previous year”
• Margin outlook: “EBITDA margins to stay stable” despite aggressive greenfield investment
• Delhi-NCR expansion: 7–8 additional centers over next 12–18 months
• Acquisition cash outflows: INR 60–65 cr in FY27; ~INR 66 cr in FY28–30 (as stated in Q&A)

Implicit signals (qualitative)

• Organic-first strategy: FY27 pipeline is all organic; partnerships only if “right price”
• Ramping risk acknowledged: new facilities require 12–18 months to stabilize; continued “drag” likely
• Premiumization remains a key lever: comfort on mature growth sustainability; higher-end procedures driving value growth

5. Standout Statements (direct quotes where useful)

• Milestone / delivery claim
• “For the first time in our company’s history, we crossed over INR 2,000 crores of revenue”
• Margin resilience despite expansion
• “This was delivered despite 19 new facility openings in the quarter” (Q4 highest quarterly EBITDA margin)
• Growth sustainability
• “we expect growth to sustain at a similar pace compared to the previous year”
• Margin stability despite capex
• “we expect our EBITDA margins to stay stable even as we continue to invest aggressively in greenfield expansion”
• Unit economics drag admission
• “FY ’26… sustained a loss of around INR30 crores… from a unit economics perspective”
• Compliance/real-estate bottleneck
• “biggest bottleneck… getting the right real estate… and… compliance… is a bit of a challenge”
• Merger timeline framing
• “July 2 is when the physical EGM will be held… expecting another five to six months…”
• Later: “expecting another five months or so” and “by end of this year, Q3…” (timeline ambiguity)

6. Red Flags / Positive Signals

Red flags
– Quantification gaps in key investor asks:
– Mature facility margin accretion: “can’t give you exactly”
– Cohort revenue tied to INR 30 cr drag: “we’ll come back…”
– Merger timeline inconsistency/ambiguity
– Multiple phrasings (“five months or so”, “five to six months”, “by end of this year Q3”) without a single clean date.
– Continued drag likely
– Management directionally agrees incremental drag may persist as surgical additions rise.

Positive signals
– Operational leverage demonstrated: Q4 EBITDA margin 30.2% despite new openings.
– Premiumization momentum: high-end cataract share and Femto growth remain strong.
– Clear capex and acquisition cash-out ranges for FY27.
– Standardization infrastructure (clinical board + optometry training pipeline) supports scaling credibility.

7. Historical Comparison & Consistency Analysis

a. Change in Tone Over Time

• Current (Q4 FY26): more confident/celebratory (INR 2,000 cr milestone; “delivered on each one”).
• Prior calls (Q3 FY26 / Q2 FY26 / Q1 FY26): also optimistic, but more process/ramp-up emphasis and fewer “milestone” declarations.
• Shift classification: More Optimistic
• More emphasis on delivery + stability (“EBITDA margins stable”, “growth similar pace”).
• Less emphasis on near-term uncertainties, though Q&A still reveals unit economics drag.

b. Tracking Past Commitments vs Outcomes

1) Capex guidance stability
– Past (Q2 FY26, Oct 31 2025): capex guidance INR 310 cr (+ INR 70 cr for flagship) remained.
– Current (Q4 FY26): FY27 outflow INR 380–400 cr (different year, but still guided with breakdown).
– Assessment: ✅ Delivered/consistent on providing capex ranges; no contradiction.

2) Break-even timing for new centers
– Past (Q2 FY26 / Q3 FY26): breakeven for new regions often 15–18 months; blended ~12 months.
– Current: reiterates 12–18 months stabilization; also admits FY26 cohort drag (~INR 30 cr).
– Assessment: ✅ Consistent (drag acknowledged but timeline maintained).

3) Merger completion expectation
– Past (Aug 12 2025 Q1 FY26): merger “outer limit of next 3 years”, and “next 1–1.5 years we should be able to get this one.”
– Current: NCLT process advanced; EGM July 2, 2026; completion expected “by end of this year, Q3” / “5–6 months”.
– Assessment: ✅ Progressing (timeline tightened), but communication is not fully crisp.

4) Unit economics drag trend
– Past (Feb 04 2026 Q3 FY26): greenfield losses discussed as cumulative; cohort-level nuance provided.
– Current: explicitly quantifies FY26 new branches drag ~INR 30 cr and compares to FY25 ~INR 21 cr.
– Assessment: ✅ More transparent now, but still not fully quantified (missing cohort revenue).

c. Narrative Shifts

• Delhi-NCR moved from “entry/traction” to “cluster scaling with quantified pipeline”
• Q1/Q2: Delhi entry described as early traction.
• Q4: Delhi-NCR becomes a major expansion engine with 7–8 additional centers guidance.
• Margin narrative shifted from “improvement” to “stability despite expansion”
• Earlier calls focused on margin improvement; now management stresses stability while acknowledging unit economics drag.
• Technology narrative strengthened
• “Neo” AI-ready system is new emphasis in Q4 FY26.

d. Consistency & Credibility Signals

• Medium credibility (improving but still uneven)
• Strength: consistent operational metrics (walk-ins, premiumization, facility counts) and repeated breakeven framing.
• Weakness: recurring inability to provide exact cohort-level numbers when asked (mature margin accretion, cohort revenue tied to drag).
• Merger timeline: credible progress, but wording varies.

e. Evolution of Key Themes

• Demand / footfall: consistently strong (walk-ins +25% YoY; ~10,000 patients/day).
• Margins: stable-to-improving at consolidated level; unit economics drag persists at cohort level.
• Expansion: acceleration continues (FY26 “one facility/week”; FY27 60 facilities).
• Refractive: earlier calls highlighted refractive as growth driver; now management acknowledges near-term softness but maintains long-term confidence.

f. Additional Insights (cross-period intelligence)

• Premiumization is doing more work than volume alone
• Q4 FY26: value growth and high-end share rising; Q&A confirms premiumization and conversion are key.
• Drag is likely structural with faster surgical additions
• Management directionally agrees incremental drag may continue as surgical openings rise in FY27—suggesting margin stability may rely on offsetting factors (premiumization, operating leverage), not elimination of early losses.
• Communication defensiveness increases when asked for precision
• When investors request exact cohort revenue/mature margin accretion, management defers (“come back separately”), which can indicate either internal complexity or reluctance to lock numbers.